Amyloidosis Therapeutics Market Report 2025 (Global Edition)

Global Amyloidosis Therapeutics Market Report 2025 Market Size Split by Treatment Outlook: (Chemotherapy, Supportive Care, Surgery, Stem Cell Transplant, Targeted Therapy), by Route of Administration ...

Amyloidosis Therapeutics Market Report Description

We have various report editions of Amyloidosis Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Amyloidosis Therapeutics Market

The market for amyloidosis therapeutics is competitive, with pharmaceutical companies making significant investments in R&D. Prothena Corporation, Johnson & Johnson, Pfizer, and Alnylam Pharmaceuticals are a few of the major participants. These businesses concentrate on creating novel medications such as RNA-targeted pharmaceuticals, gene therapies, and monoclonal antibodies. To speed up medication development, biotech companies and academic universities frequently collaborate and form partnerships. Regulatory clearances, geographical expansion, and improvements in clinical trials are examples of competitive strategy. Newcomers provide specialized treatments for particular forms of amyloidosis. The rising market for rare illness medications and the unmet clinical need are driving the level of competition.

In October 2024, WAINZUA (eplontersen), a medication of Ionis Pharmaceuticals, Inc. and AstraZeneca, has been proposed for approval by the European Union's (EU) Committee for Medicinal Products for Human Use (CHMP) to treat hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, also known as hATTR-PN or ATTRv-PN.

(Source:https://ir.ionis.com/news-releases/news-release-details/wainzua-eplontersen-recommended-approval-eu-chmp-treatment)

In October 2023, The major RNAi therapeutics company, Alnylam Pharmaceuticals, Inc., revealed that the New England Journal of Medicine (NEJM) had published online the findings of the APOLLO-B Phase 3 study of investigational patisiran in patients with the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.

(Source:https://investors.alnylam.com/press-release?id=27766)

In January 2021, Johnson & Johnson's Janssen Pharmaceutical Companies disclosed that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, has been approved by the FDA in the United States for use in treating adult patients with newly diagnosed light chain (AL) amyloidosis when combined with bortezomib, cyclophosphamide, and dexamethasone (D-VCd).

Top Companies Market Share in Amyloidosis Therapeutics Industry: (In no particular order of Rank)

• Pfizer Inc.
• Johnson & Johnson Services Inc.
• GSK plc.
• Takeda Pharmaceutical Company Limited
• Alnylam Pharmaceuticals Inc.
• Sanofi
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Ionis Pharmaceuticals
• Bristol-Myers Squibb Company
• Amgen Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Amyloidosis Therapeutics Market

Which Region Dominates the Amyloidosis Therapeutics Market in 2024?

According to Cognitive Market Research, North America currently dominates the Amyloidosis Therapeutics market, and the region is expected to have significant growth during the projected period. The market for amyloidosis therapeutics in North America is expanding significantly as a result of improved treatment choices and growing awareness of uncommon illnesses. The US market is supported by significant R&D expenditures, a high incidence of amyloidosis, and advantageous reimbursement regulations. Through government funding for treatments for rare diseases and an increasing emphasis on precision medicine, Canada presents chances. The existence of top pharmaceutical businesses and cutting-edge healthcare facilities benefits both nations. Emerging trends that are opening up new possibilities for innovation and better patient outcomes in the area include the use of gene-editing technology, RNA-based medicines, and personalized medicine techniques.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Increased recognition of uncommon diseases and increased healthcare investments are driving growth in the Asia-Pacific market for amyloidosis therapeutics. Government programs encouraging the study of rare diseases, growing healthcare facilities, and domestic biotech advancements are driving growth in China. India presents prospects by expanding clinical trials, lowering manufacturing costs, and expanding access to cutting-edge therapies. Government incentives for orphan medications and a robust pharmaceutical sector propel Japan's acceptance of innovative therapies to the forefront. Improved access to healthcare and awareness efforts are driving up demand in Southeast Asian nations. Opportunities in the market are greatly increased by the region's emphasis on biopharmaceutical development and partnerships.

The current report Scope analyzes Amyloidosis Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Amyloidosis Therapeutics Market Analysis

According to Cognitive Market Research, the global Amyloidosis Therapeutics market size was estimated at USD XX Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Amyloidosis Therapeutics market with a market size of USD XX million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. Growing amyloidosis awareness and diagnosis in the United States.
• The Canada Amyloidosis Therapeutics market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. In Canada, there is a growing focus on rare disease treatments and personalized medicine.
• The Mexico Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD XX million in 2024.

Europe Amyloidosis Therapeutics Market Analysis

According to Cognitive Market Research, the global Amyloidosis Therapeutics market size was estimated at USD XX Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.

• The United Kingdom Amyloidosis Therapeutics market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. Government support for UK research and treatment of amyloidosis.
• The France Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD XX million in 2024.
• According to Cognitive Market Research, the German Amyloidosis Therapeutics market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. Germany's robust pharmaceutical sector contributes to drug development.
• The Italy Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD XX million in 2024.
• The Russia Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD XX million in 2024.
• The Spain Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 5.6% during the forecast period with a market size of USD XX million in 2024
• The Luxembourg Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 6.6% during the forecast period, with a market size of USD XX million in 2024.
• The Portugal Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD XX million in 2024.
• The Greece Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of Europe's Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD XX million in 2024.

Asia Pacific Amyloidosis Therapeutics Market Analysis

According to Cognitive Market Research, the global Amyloidosis Therapeutics market size was estimated at USD XX Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Amyloidosis Therapeutics market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. China's government is working to enhance healthcare and provide access to specialist therapies.
• The Japan Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD XX million in 2024.
• The India Amyloidosis Therapeutics market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. In India, uncommon disease awareness and diagnosis are rising.
• The South Korean Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 9.1% during the forecast period, with a market size of USD XX million in 2024.
• The Australian Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD XX million in 2024.
• The South East Asia Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 11.0% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of Asia Pacific Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD XX million in 2024.

South America Amyloidosis Therapeutics Market Analysis

According to Cognitive Market Research, the global Amyloidosis Therapeutics market size was estimated at USD XX Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Amyloidosis Therapeutics market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. Initiatives taken by the Brazilian government to combat uncommon diseases.
• Argentina's Amyloidosis Therapeutics market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. Argentina's rising awareness and access to healthcare.
• Colombia Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD XX million in 2024.
• Peru Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD XX million in 2024.
• Chile's Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of Latin America's Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD XX million in 2024.

Middle East Amyloidosis Therapeutics Market Analysis

According to Cognitive Market Research, the global Amyloidosis Therapeutics market size was estimated at USD XX Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031..

• The GCC Countries Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD XX million in 2024. Increasing attention in the GCC countries on managing rare diseases.
• The Egypt Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD XX million in 2024.
• The South Africa Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD XX million in 2024. Improved South African healthcare infrastructure has contributed to a rise in the use of cutting-edge treatments for rare medical conditions.
• The Turkey Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD XX million in 2024.
• The Nigeria Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of the MEA Amyloidosis Therapeutics market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD XX million in 2024.

Amyloidosis Therapeutics Market Analysis

How are Segments Performing in the Global Amyloidosis Therapeutics Market?

Amyloidosis Therapeutics Market Treatment Segment Analysis

According to Cognitive Market Research, Chemotherapy is likely to dominate the Amyloidosis Therapeutics Market over the forecast period. This is because of its efficacy in treating amyloidosis, especially AL amyloidosis. Chemotherapy reduces the synthesis of these dangerous proteins and relieves symptoms by destroying the aberrant plasma cells that make amyloid proteins. Recent advancements in chemotherapy have produced safer and more effective medications, which have improved patient outcomes and decreased adverse effects, making chemotherapy a feasible treatment choice for amyloidosis. Additionally, supportive care and chemotherapy help patients live longer and have higher quality of life.

The Stem Cell Transplant category is the fastest-growing segment in the Amyloidosis Therapeutics Market. In order to cure some forms of amyloidosis, especially systemic amyloidosis brought on by abnormalities of the plasma cells, stem cell transplantation is essential. Because it can successfully stop the generation of aberrant amyloid proteins by replacing sick or damaged bone marrow with healthy stem cells, this therapy is in high demand. Because of their superior hematopoietic stem cell transplantation skills and sophisticated healthcare systems, North America and Europe are the most adopting regions. Growth in emerging countries in Asia-Pacific is also being driven by improvements in transplant technologies and easier access to specialist medical care, which is opening up more prospects in the global market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Amyloidosis Therapeutics Industry. Request a Free Sample PDF!

Amyloidosis Therapeutics Market Route of Administration Segment Analysis

According to Cognitive Market Research, the oral route of administration segment holds the largest share of the market. Because of its ease of use, non-invasiveness, and patient compliance, the oral route of administration is becoming increasingly popular in the market for amyloidosis therapeutics. Amyloidosis medications, such as tafamidis and doxycycline, are frequently designed to be used orally, allowing patients to manage their condition at home easily. In developed regions like North America and Europe, where modern medicines are readily accessible, demand is especially high. As healthcare systems improve and oral medicines become more accessible, emerging markets in Asia-Pacific are also expanding. Patient adherence and results are improved by the increased demand for oral medications, which is in line with the trend of individualized therapy.

In the Amyloidosis Therapeutics Market, the Injectable category has been expanding at a rapid pace. In the market for amyloidosis therapeutics, the injectable method of administration is highly sought after due to its effectiveness in delivering exact dosages straight into the bloodstream for quick therapeutic benefits. Commonly given by injection, treatments including monoclonal antibodies and other biologics, such as patisiran and daratumumab, efficiently treat severe cases of amyloidosis. For hospital-based and specialized care, this is the most popular option, particularly in developed areas like North America and Europe. Expanded use of injectable medications is being made possible in emerging markets by better healthcare infrastructure. Their experimental efficacy is what drives demand, especially for systemic forms of amyloidosis that need rigorous therapy.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Amyloidosis Therapeutics Drugs Outlook: Segment Analysis

Amyloidosis Therapeutics Market Drugs Segment Analysis

According to Cognitive Market Research, The Transthyretin Transport Inhibitor segment holds the largest market share. Transthyretin transport inhibitors' focused approach to treating transthyretin amyloidosis (ATTR) is what propels their demand in the amyloidosis therapeutics market. A major contributing cause to the development of ATTR is the misfolding of transthyretin proteins, which is prevented by medications like tafamidis and diflunisal. Because of their capacity to reduce the progression of the disease, especially in patients with wild-type and hereditary ATTR, these inhibitors are becoming more and more chosen. Demand has also increased as a result of improvements in genetic testing and imaging that have led to more early detection. Continuous clinical trials to broaden their indications and growing physician and patient awareness are driving this segment's growth on a global scale.

In the Amyloidosis Therapeutics market, the rapidly growing sector is Immunomodulatory Drugs. Immunomodulatory medications are becoming more popular in the market for amyloidosis therapeutics because they help treat light chain (AL) amyloidosis by addressing the underlying problems with plasma cells. Medications that alter immune responses and prevent aberrant plasma cell growth, such as lenalidomide and pomalidomide, are frequently used in combination therapy for successful treatment. Improvements in medication formulations and the rising incidence of AL amyloidosis are driving the need for these medicines. Their growing popularity is also being aided by improving survival rates linked to immunomodulatory therapy and a greater emphasis on individualized care. The goal of ongoing studies and clinical trials is to increase their effectiveness, which will support market expansion even further.

• Transthyretin Transport Inhibitor
• Immunomodulatory Drugs
• Monoclonal Antibodies
• Proteasome Inhibitors
• Others

Amyloidosis Therapeutics Distribution Channel Outlook: Segment Analysis

Amyloidosis Therapeutics Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the Hospital Pharmacies segment dominates the market. Due to the growing incidence of the disease and improvements in available treatments, hospital pharmacists are essential to the amyloidosis therapeutics market. These pharmacies meet the demand for specialty medications, such as immunomodulatory agents, transthyretin transport inhibitors, and supportive care therapies. Since hospitals are frequently the initial location for amyloidosis diagnosis and treatment, their pharmacies play a critical role in guaranteeing prompt access to these treatments. The expanding use of stem cell transplants and sophisticated injectable therapies increases the need for hospital pharmacists. Furthermore, patient monitoring programs and clinical trials conducted in hospitals increase the demand for medications administered through this channel.

Online Pharmacies are projected to be the fastest-growing segment in the Amyloidosis Therapeutics market. Online pharmacies are becoming more and more popular in the amyloidosis therapeutics market because of their affordable, easily accessible, and convenient products. These platforms give patients, particularly those living in rural or underdeveloped areas, access to specific amyloidosis treatments, such as transthyretin transport inhibitors and immunomodulatory therapies. Online pharmacy services are growing as a result of the necessity for long-term medication management and the increased prevalence of chronic diseases. E-prescriptions and telemedicine are also becoming more widely used, which makes ordering and delivery easier. The amyloidosis therapeutics online pharmacy market is expanding due to its competitive pricing, discrete purchase alternatives, and subscription-based business models.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Author's Detail

Aarti Bagekari

Research Associate at Cognitive Market Research

LinkedIn

Profile

I am Aarti Bagekari, worked as a research associate with strong passion for transforming complex information into strategic insights. My strong analytical skills, coupled with a deep understanding of market dynamics and consumer behavior, empower me to identify hidden opportunities and proactively mitigate risks for clients. As a part of team, I possess a skills in data analysis, segmentation, competitive landscape.

Author's Conclusion